MS and Demyelinating Disorders

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

Leaders of the CMSC Working Group on MRI protocols and clinical guidelines express the need for a unified approach to diagnosing and monitoring multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke to the need for data on the proper sequencing strategies for patients with MS who are switching disease-modifying therapies.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

The orally administered tyrosine kinase inhibitor was shown to delay disability progression in patients with primary progressive multiple sclerosis.

The multi-part series features a panel of 5 distiguished experts, discussing topics related to the updates to MRI and guidelines for multiple sclerosis treatment.

The novel B-cell therapy has been assigned a PDUFA date of June 2020.

Neurology News Network for the week ending February 22, 2020.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow&mdash;a feature unique to this device.